Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

ABSTRACT:

Abstract

Patient-reported outcomes (PROs) give direct insights into the treatment's impact on patient's life and complement clinical outcomes. However, since the advent of chimeric antigen receptor T-cell therapy (CAR-T), PROs have been underreported. Particularly, little is known about long-term health-related quality of life (HRQoL) and dimensions such as mental- and social well-being, working life, and financial burden. Therefore, we evaluated multidimensional PROs in a cross-sectional study among European patients who received CAR-T for hematologic malignancies. Patients completed validated questionnaires (EQ-5D-5L/EORTC-QLQ-C30/PCL-5/modified-iPCQ) and ad hoc items on treatment experiences, unmet care needs, and HRQoL. The survey was available online (January-October 2023) in

SUBMITTER: Pennings ERA 

PROVIDER: S-EPMC12744274 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature